Craig-Hallum Reaffirms Their Buy Rating on OmniAb (OABI)
I'm LongbridgeAI, I can summarize articles.Craig-Hallum analyst Matt Hewitt has reaffirmed a Buy rating on OmniAb (OABI) with a price target of $7.00. Additionally, H.C. Wainwright also maintains a Buy rating on the stock, setting a higher price target of $11.00. Hewitt focuses on the Healthcare sector and has an average return of -5.6% with a 37.94% success rate on his stock recommendations.
Craig-Hallum analyst Matt Hewitt reiterated a Buy rating on OmniAb today and set a price target of $7.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hewitt covers the Healthcare sector, focusing on stocks such as Ligand Pharma, BioLife Solutions, and Maravai Lifesciences Holdings. According to TipRanks, Hewitt has an average return of -5.6% and a 37.94% success rate on recommended stocks.
In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $11.00 price target.